Skip to main content

Table 5 Clinical Outcomes of the Study Patients with and without CMV Reactivation

From: Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study

 

Overall

CMV Reactivation

 
 

N = 71

Yes (n = 13, 18.3%)

No (n = 58, 81.7%)

P

Complications, n (%)&a

54 (76.1)

13 (100)

41 (70.7)

0.06

Blood Transfusion in ICU, n (%)

52 (73.2)

12 (92.3)

40 (69.0)

0.17

Length of IMV (d)b

13 (8–20)

25 (20–45)

10 (8–18)

 < 0.01

Hospitalization Expenses (million/Â¥)a

0.18 (0.11–0.26)

0.35 (0.35–0.23)

0.16 (0.11–0.23)

0.02

Length of Hospital Stay (d)

29 (17–50)

50 (27–61)

28 (17–41)

0.10

ICU Length of Stay (d)b

14 (9–20)

27 (20–45)

12 (8–18)

 < 0.01

28 day All-Cause Mortality, n (%)

17 (23.9)

5 (38.5)

12 (20.7)

0.32

90 day All-Cause Mortality, n (%)b

20 (28.2)

9 (69.2)

11 (19.0)

 < 0.01

  1. aP < 0.05; bP < 0.01; Continuous variables were expressed as Mean ± SD or Median (IQRs); Bold font indicates the comparisons with statistical significance; &At least one of the following complications—urinary tract infection, ventilator-associated pneumonia, gastric hemorrhage, disseminated intravascular coagulation, or acute heart failure; IMV Invasive Mechanical Ventilation